Evaluation of anthropometric and cardiometabolic changes and their implications on cardiovascular risk in adults with obesity and metabolic syndrome at a university hospital in the amazon region
Main Article Content
Keywords
Metabolic Syndrome, obesity, risk factors, cardiovascular diseases
Abstract
Background: To analyze the impact of obesity and MS on cardiovascular risk and cardiac conditions with obesity with and without MS. Methods: The study conducted was a descriptive retrospective cross-sectional study, carried out with obese patients under care at the Cardiology Outpatient Clinic of João Barros Barreto University Hospital in Belém/PA. Inclusion criteria included individuals over 18 years old, diagnosed with obesity with or without Metabolic Syndrome, and who had updated laboratory, electrocardiographic, and echocardiographic exams available. The study was conducted in 2023 and is part of the project approved under opinion No. 69722423.30000.0018. The Chi-square test was used to describe the relationship between variables, with statistically significant values considered as hypothesis tests with p <0.05. Results: The study evaluated 100 individuals with obesity, of which 60 had MS, with a mean age of 54 years and a prevalence of females. There was an association between the presence of high Framingham Risk Score (FRS) and changes in BMI, waist circumference, systolic blood pressure (SBP), HDL, triglycerides, total cholesterol, and glucose indices for both groups. There was an association between the presence of MS and high FRS in women. Conclusion: Thus, in both groups, there was a occurrence of high FRS, especially in obese women. Obese individuals without MS have a similar risk, requiring appropriate attention to the cardiac health of such individuals.
References
Prevention of Cardiovascular Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. NLM (Medline). 2019;140(11):e596-e646. https://doi.org/10.1161/cir.0000000000000678
2. Associação Brasileira para o Estudo da Obesidade e da Síndrome Metabólica Diretrizes brasileiras de obesidade 2016 / ABESO- Associação Brasileira para o Estudo da Obesidade e da Síndrome Metabólica. - 4.ed. - São Paulo, SP
3. De Carvalho Vidigal F, Bressan J, Babio N, Salas-Salvadó J. Prevalence of metabolic syndrome in Brazilian adults: A systematic review. BMC Public Health. 2013;13(1):1-10. https://doi.org/10.1186/1471-2458-13-1198
4. Oliveira DS, Tannus LR, Matheus AS, Corrêa FH, Cobas R, Cunha EF, et al. Avaliação do risco cardiovascular segundo os Critérios de Framingham em pacientes com diabetes tipo 2. Arq Bras Endocrinol Metab. 2007;51(2):26874.
https://doi.org/10.1590/s0004-27302007000200015
5. Barroso TA, Marins LB, Alves R, Gonçalves ACS, Barroso SG, Rocha G de S. Associação Entre a Obesidade Central e a Incidência de Doenças e Fatores de Risco Cardiovascular. Int j Cardiovasc sci. 2017;30(5):416-24.
6. Espinosa De Ycaza AE, Donegan D, Jensen MD. Long-term metabolic risk for the metabolically healthy overweight/obese
phenotype. Int J Obes (Lond). 2018;42(3):302-9. https://doi.org/10.1038/ijo.2017.233
7. Caleyachetty R, Thomas GN, Toulis KA, Mohammed N, Gokhale KM, Balachandran K, et al. Metabolically Healthy Obese and Incident Cardiovascular Disease Events Among 3.5 Million Men and Women. J Am Coll Cardiol. 2017;70(12):1429-37. https://doi.org/10.1016/j.jacc.2017.07.763
8. Eckel N, Meidtner K, Kalle-Uhlmann T, Stefan N, Schulze MB. Metabolically healthy obesity and cardiovascular events: A systematic review and meta-analysis. Eur J Prev Cardiol. 2016;23(9):956-66. https://doi.org/10.1177/2047487315623884
9. Moussa O, Arhi C, Ziprin P, Darzi A, Khan O, Purkayastha S. Fate of the metabolically healthy obese-is this term a misnomer: A study from the Clinical Practice Research Datalink. Int J Obes (Lond). 2019;43(5):1093-1101. https://doi.org/10.1038/s41366-018-0096-z
10. Kramer CK, Zinman B, Retnakaran R. Are metabolically healthy overweight and obesity benign conditions: A systematic review and meta-analysis. Ann Intern Med. 2013;159(11):758-69. https://doi.org/10.7326/0003-4819-159-11-201312030-00008
11. Caleyachetty R, Thomas GN, Toulis KA, Mohammed N, Gokhale KM, Balachandran K, et al. Metabolically Healthy Obese and Incident Cardiovascular Disease Events Among 3.5 Million Men and Women. J Am Coll Cardiol. 2017;70(12):1429-37. https://doi.org/10.1016/j.jacc.2017.07.763
12. Prospective Studies Collaboration, Whitlock G, Lewington S, Sherliker P, Clarke R, Emberson J, et al. Body-mass index and cause-specific mortality in 900 000 adults: collaborative analyses of 57 prospective studies. Lancet. 2009;373(9669):1083-96. https://doi.org/10.1016/s0140-6736(09)60318-4
13. Teixeira RJ, Leite AB, Farias CA, Sousa CR, Yugue AM, Aguiar AA, et al. Aumento do risco cardiovascular em mulheres com síndrome metabólica. Rev Bras Med Fam Com. 2008;3(12):23746.
14. Cho L, Davis M, Elgendy I, Epps K, Lindley KJ, Mehta PK, et al. Summary of Updated Recommendations for Primary Prevention of Cardiovascular Disease in Women: JACC State-of-the-Art Review. J Am Coll Cardiol. 2020;75(20):2602-18. https://doi.org/10.1016/j.jacc.2020.03.060
15. Nascimento JS, Gomes B, Sardinha AH. Fatores de risco modificáveis para as doenças cardiovasculares em mulheres com hipertensão arterial. Rev Rene. 2011;12(4):70915.
16. Mendes WA, Carmin SE, Pinho PM, Silva AC, Machado LM, Araújo MS. Relação de Variáveis Antropométricas com os Perfis Pressórico e Lipídico em Adultos Portadores de Doenças Crônicas Não Transmissíveis. Rev Bras Cardiol. 2012;25(3):2009
17. Fernandes M, Paes C, Nogueira C, Souza G, Aquino L, Borges F, et al. Perfil de consumo de nutrientes antioxidantes em pacientes com Síndrome Metabólica. Rev Ciênc Méd. 2007;16(46):20919.
18. Alves LR, Coutinho V, Santos LC. Indicadores antropométricos associados ao risco de doença cardiovascular. Arq Sanny Pesq Saúde. 2008;1(1):1-7.
19. Ferreira MG, Valente JG, Gonçalves-Silva RMV, Sichieri R. Acurácia da circunferência da cintura e da relação cintura/quadril como preditores de dislipi- demias em estudo transversal de doadores de sangue de Cuiabá, Mato Grosso, Brasil. Cad Saúde Pública 2006;22(2):307-14. https://doi.org/10.1590/s0102-311x2006000200008
20. Gharakhanlou R, Farzad B, Agha-Alinejad H, Steffen LM, Bayati M. Medidas antropométricas como preditoras de fatores de risco cardiovascular na população urbana do Irã. Arq Bras Cardiol. 2012;98(2):126-35. https://doi.org/10.1590/S0066-782X2012005000007
21. Machado SP, Rodrigues DG, Viana KD, Sampaio HA. Correlação entre o índice de massa corporal e indicadores antropométricos de obesidade abdominal em portadores de diabetes mellitus tipo 2. Rev Bras Prom Saúde. 2012;25(4):51220.
22. Nobre LN, Esteves EA, Silva KC, Moreira LL, Dias AM, Coelho NF, et al. Fatores de risco modificáveis para doenças cardiovasculares: efeito de um programa de educação. Alim Nutr (Araraquara). 2012;23(4):6719.
23. Fornés NS, Martins IS, Velásquez-
Meléndez G, Latorre MRDO. Escores de consumo alimentar e níveis lipêmicos em população de São Paulo, Brasil. Rev Saúde Pública. 2002;36(1):128.
24. Oliveira DS, Tannus LR, Matheus AS, Corrêa FH, Cobas R, Cunha EF, et al. Avaliação do risco cardiovascular segundo os Critérios
de Framingham em pacientes com diabetes tipo 2. Arq Bras Endocrinol Metab. 2007;51(2):26874.
25. Bradshaw PT, Reynolds KR, Wagenknecht LE, Ndumele CE, Stevens J. Incidence of components of metabolic syndrome in
the metabolically healthy obese over 9 years follow-up: the Atherosclerosis Risk In Communities study. Int J Obes (Lond). 2018;42(3):295-301. https://doi.org/10.1038/ijo.2017.249
26. Peterson LR. Obesity and insulin resistance: effects on cardiac structure, function, and substrate metabolism. Curr Hypertens Rep. 2006;8(6):451-6. http://dx.doi.org/10.1007/s11906-006-0022-y
27. Machado RC, De Paula RB, Ezequiel DG, Chaoubach A, Costa MB. Risco cardiovascular na síndrome metabólica: estimativa por diferentes escores. Rev Bras Clin Med. 2010;8(3):198204.
28. Rosini N, Rosini AD, Mousse DM, Rosini GD. Prevalência de síndrome metabólica e estratificação de risco para DAC em pacientes hipertensostabagistas. RBAC. 2007;39(3):2236.
29. Cavalera M, Wang J, Frangogiannis NG. Obesity, metabolic dysfunction, and cardiac fibrosis: pathophysiological pathways,molecular mechanisms, and therapeutic opportunities. Transl Res. 2014;164(4):323-35. http://dx.doi.org/10.1016/j.trsl.2014.05.001
Article Sidebar
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.